Meeting
2019 ASCO Annual Meeting
Chemotherapy in KRAS-mutated chemotherapy naive non-small cell lung cancer patients: A phase III comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab: NVALT 22 (NCT02743923).
Authors
Anne-Marie C. Dingemans
Maastricht University Medical Center, Maastricht, Netherlands
Anne-Marie C. Dingemans , Egbert F. Smit , Joop De Langen , Harm van Tinteren
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02743923
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS9127)
DOI
10.1200/JCO.2019.37.15_suppl.TPS9127
Abstract #
TPS9127
Poster Bd #
443b
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Retrospective analysis of type of KRAS mutation (mut) and response to first-line platinum-based chemotherapy (PC) in non-small cell lung cancer (NSCLC) patients (pts).
First Author: Wouter Willem Mellema
Poster
2016 ASCO Annual Meeting
Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.
First Author: Vassiliki Papadimitrakopoulou
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu
Poster
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
First Author: Yuming Zhu